Sandoz Says Neulasta Biosimilar Doesn't Infringe Amgen IP
Sandoz Inc. urged a California federal judge Monday to find it hadn't infringed Amgen Inc.'s patent related to the biologic Neulasta, which treats chemotherapy side effects, because the recipe for Sandoz's...To view the full article, register now.
Already a subscriber? Click here to view full article